Back to search results
NCT07222605

Research Study for Patients With Neurological Diseases Which Evaluates the Patient Experience of the MemorEM Device

Enrolling by Invitation
NAAges 45+Interventional
eQ8Health Corporation d/b/a CareONE Concierge
~1,000 participants
Updated 2026-02-05 on ClinicalTrials.gov
What's tested:MemorEM

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Patient and caregiver reports on device design and use
Measured over Surveys will be given starting a month after beginning treatment and monthly thereafter over the course of up to two years.

Conditions

Alzheimer Disease
Parkinson Disease
Frontotemporal Dementia
Cortico Basal Degeneration
Posterior Cortical Atrophy (PCA)
Neurological Diseases or Conditions
Dementia

Explore related trials

Alzheimer's DiseaseAmyotrophic Lateral SclerosisFrontotemporal DementiaParkinson DiseasePosterior cortical atrophy syndromeTauopathiesUrinary System Disorder

NCT07222605

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • CareONE Concierge

    Atlanta, Georgiano site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Jason M Cavolina, PharmD · PRINCIPAL_INVESTIGATOR · Principal Investigator

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient diagnosed with a neurological disease involving aggregated proteins such as Alzheimer's and its variants, Parkinson's, Frontotemporal dementia, Amyotrophic lateral sclerosis, Tauopathies, and other related neurological diseases.
Presence of a caregiver(s) responsible for ensuring treatment compliance and potentially with authority to make medical decisions for the patient if the patient is not competent to make those decisions.
A statement from each patient's physician that indicates the patient has the ability to understand and consent on their own AND they have the willingness to sign CareONE's patient consent.

Exclusion

Patient has Seizures, Epilepsy, uncontrolled Depression, uncontrolled Bipolar disorder, psychotic disorders, alcoholism or drug addiction
Presence of metal implants in the head, except for metal dental implants
Patient has hypertension that is unresponsive to anti-hypertensive medications
Patient has implanted medication pumps unless cleared by physician
Patient has significant heart disease, as determined by a physician

What this trial measures

  • Patient and caregiver reports on device design and useSurveys will be given starting a month after beginning treatment and monthly thereafter over the course of up to two years.

    The primary objective of this pilot study is to gain voluntary feedback from patients with neurological diseases and their caregivers regarding their experiences using the MemorEM head device. This information will be gathered via a monthly survey. This information may help in new designs of the MemorEM and suggest ways to increase compliance for future clinical trials and eventual commercialization.